PRODUCT INFORMATION

Contents: Anti-hEGFR-hIgG1 purified monoclonal antibody (mAb) is provided azide-free and lyophilized. It is available in two quantities:
- hegfr-mab1: 100 μg Anti-hEGFR-hIgG1
- hegfr-mab1-1: 1 mg Anti-hEGFR-hIgG1

Specificity: Epidermal growth factor receptor (EGFR)
Isotype: Human IgG1
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Antibody resuspension
Note: Ensure you see the lyophilized pellet before resuspension.
- Add 1 ml of sterile water to 100 μg to obtain a stock solution at 100 μg/ml.
- Add 1 ml of sterile water to 1 mg to obtain a stock solution at 1 mg/ml.
  - Gently pipette until completely resuspended.

Storage and stability
- Product is shipped at room temperature. Upon receipt, store at -20°C.
- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control
- Binding of anti-hEGFR-hIgG1 to human EGFR has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hEGFR-hIgG1 features the constant region of the human IgG1 isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor-α. Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis. Binding of cetuximab to EGFR blocks ligand-receptor binding and induces receptor internalization and subsequent degradation. Consequently, cetuximab blocks downstream pathways which regulate cell growth and angiogenesis. In addition, cetuximab induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) \(^1\). Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck \(^2\).

Anti-hEGFR-hIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-β-Gal-hIgG1</td>
<td>bgal-mab1</td>
</tr>
</tbody>
</table>

Other antibody isotype families are available, such as Anti-hCD20, Anti-hPD1 and Anti-β-Gal(control). For more information, please visit www.invivogen.com/biosimilar-antibody-isotypes.